May 21, 2026 06:28 ET  | Source: Junshi Biosciences SHANGHAI, May 21, 2026 (GLOBE NEWSWIRE) — Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that the new drug application (NDA) for toripalimab in combination with disitamab vedotin for […]

Cardiovascular and Respiratory medicines to be supplied in Malaysia and the Philippines May 21, 2026 05:06 ET  | Source: Hanmi Pharmaceutical Shin Hae-gon (right), Head of Overseas Sales at Hanmi Pharmaceutical, and Andreas Daugaard Jørgensen (left), Managing Director, Organon Asia Pacific Cluster, met at Organon’s Malaysia office to discuss the expansion of Hanmi’s combination therapies into the

May 19, 2026 09:00 ET  | Source: Curia Global, Inc. ALBANY, N.Y., May 19, 2026 (GLOBE NEWSWIRE) — Curia Global, Inc. (Curia), a leading global research, development and manufacturing organization, today announced the completion of its upgrade to its two aseptic suites in Valladolid, Spain. The $4 million dollar investment is in accordance with the EU’s GMP

May 19, 2026 08:24 ET  | Source: Risen Pharma Tech Co., Ltd SHANGHAI, May 19, 2026 (GLOBE NEWSWIRE) — Risen Pharma, a clinical-stage biotech company focusing on the development and commercialization of high-need, patient-accessible therapeutics, today announced the initiation of a Phase 2 clinical study in China of RP902, an oral small-molecule drug developed to address significant unmet

May 18, 2026 11:00 ET  | Source: Royal Philips May 18, 2026 From imaging to AI-enabled guidance, Philips connects technologies into a unified workflow to improve efficiency, reduce radiation exposure and support procedural confidenceAmsterdam, the Netherlands – As cardiac procedures become more complex, interventional cardiologists must balance the need for precise imaging and decision-making with growing pressure to

May 18, 2026 10:00 ET  | Source: Royal Philips May 18, 2026      Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced Philips SmartIQ, a breakthrough coronary imaging technology for its Azurion image-guided therapy. Developed in collaboration with leading cardiovascular centers, SmartIQ is designed to address one of the field’s most

May 18, 2026 08:30 ET  | Source: Teva Pharmaceutical Industries Ltd TEL AVIV, Israel, May 18, 2026 (GLOBE NEWSWIRE) — Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Fitch Ratings Agency (“Fitch”) has raised the Company’s corporate credit rating to Investment Grade BBB-, with a stable outlook, from BB+. “This strong endorsement, our third

May 18, 2026 08:00 ET  | Source: Teva Pharmaceutical Industries Ltd PARSIPPANY, N.J. and TEL AVIV, Israel, May 18, 2026 (GLOBE NEWSWIRE) — Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced new data from the ongoing, real-world IMPACT-TD Registry, highlighting a significant gap in diagnosing tardive dyskinesia (TD) in

May 18, 2026 04:00 ET  | Source: Royal Philips May 18, 2026 Philips-led consortium selected through Karolinska University Hospital-led Region Stockholm tender to deliver advanced remote monitoring for complex patients Stockholm, Sweden – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced that a consortium composed of Philips, Cuviva and Vingmed has been selected

May 18, 2026 02:00 ET  | Source: Boehringer Ingelheim Limited Not intended for UK and US audiences Boehringer Ingelheim today announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved JASCAYD® (nerandomilast) for the treatment of adults with idiopathic pulmonary fibrosis (IPF) and adults with progressive pulmonary fibrosis (PPF). It is the first phosphodiesterase 4B (PDE4B) inhibitor

May 14, 2026 16:05 ET  | Source: Zymeworks Inc. VANCOUVER, British Columbia, May 14, 2026 (GLOBE NEWSWIRE) — Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced that its Board of Directors has authorized a 2026 share repurchase program under which

Investigational New Drug application for KHN921 received “study may proceed” from the US FDA. KHN921 is a potential “first-in-class” cardiovascular AAV gene therapy being developed for the treatment of hypertrophic cardiomyopathy (HCM) associated with MYBPC3 mutations May 13, 2026 14:09 ET  | Source: Vanotech Ltd CHENGDU, China and ROCKAWAY, N.J., May 13, 2026 (GLOBE NEWSWIRE) — Chengdu

The presentation will examine PPWR minimization-driven blister innovations, including recyclable and recycled pharmaceutical grades. Company will also showcase its advanced barrier materials and expanded multidose vial capabilities May 13, 2026 10:22 ET  | Source: TekniPlex Wayne, PA, May 13, 2026 (GLOBE NEWSWIRE) — TekniPlex Healthcare, which utilizes advanced materials science expertise to help deliver better patient outcomes, will exhibit and present at The Pharma Days

May 13, 2026 09:41 ET  | Source: Sabin Vaccine Institute WASHINGTON, May 13, 2026 (GLOBE NEWSWIRE) — The 2026 Sabin Awards were presented yesterday at the National Academy of Sciences building in Washington, D.C., with Professor Uğur Şahin, MD, and Professor Özlem Türeci, MD, receiving the Sabin Vaccine Institute’s Albert B. Sabin Gold Medal for their role

May 13, 2026 06:00 ET  | Source: Zymeworks Inc. VANCOUVER, British Columbia, May 13, 2026 (GLOBE NEWSWIRE) — Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced that management will participate in the following upcoming investor conferences: About Zymeworks Inc. Zymeworks